Combining Ultivue’s mIF assays with the Olympus SLIDEVIEW™ VS200 research slide scanner provides a convenient, fast tool for whole slide mIF imaging in translational studies for researchers in academia, biotech, pharma and contract research organizations in the Americas. The collaboration builds on their existing partnership to meet the scientific community’s increasing need for fluorescent multiplexing.
Ultivue develops unique solutions for mIF applications, imaging and spatial phenomics. Its proprietary InSituPlex® technology enabling improved signal-to-noise data is designed for fast and comprehensive exploration of up to 12 biologically relevant targets in one tissue slide, with same-slide hematoxylin and eosin (H) analysis in tissue samples. This technology combines the power of computational pathology and spatial biology to guide translational science in immuno-oncology.
Evident Corporation, a wholly owned subsidiary of Olympus Corporation, manufacturers leading-edge life science microscopes that support a broad range of academic and clinical research areas, pathology diagnostic services and the growing demand for novel drug discovery. The Olympus VS200 slide scanner has advanced the field of whole slide imaging with high-quality optics, fast scanning and flexible imaging options that include a robust solution for fluorescent multiplexing.
“We are excited to enhance our relationship with Evident to further optimize the integration of Ultivue assays on the SLIDEVIEW VS200 research slide scanner. We jointly enable highly efficient workflows to drive adoption of tissue multiplexing on larger cohorts,” said Florian Leiss, PhD, the Vice President of Product Strategy and Corporate Development at Ultivue.
“We are delighted to continue to collaborate with Ultivue to provide a total solution for multiplexing,” said Lee Wagstaff, the Vice President of Life Science Sales and Marketing at Evident Americas. “With Ultivue’s assays and our slide scanning technology, we can provide a complete workflow solution for our customers that enables them to work more efficiently.”
At Evident, we are guided by the scientific spirit—innovation and exploration are at the heart of what we do. Committed to making people’s lives healthier, safer and more fulfilling, we support our customers with solutions that solve their challenges and advance their work, whether it is researching medical breakthroughs, inspecting infrastructure, or exposing hidden toxins in consumer products.
Evident Life Science empowers scientists and researchers through collaboration and cutting-edge life science solutions. Dedicated to meeting the challenges and supporting the evolving needs of its customers, Evident Life Science advances a comprehensive range of microscopes for pathology, hematology, IVF, and other clinical applications as well as for research and education.
For more information, EvidentScientific.com.
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at ultivue.com.Eva Categories: News Tags: Announcement 6640 Ultivue and ZEISS to Co-Market Complete Solution for Spatial Phenomics
Ultivue VUE panels for multiplex immune-labeling offer endless options for researchers to characterize complex, tissue immune biology. With unprecedented signal-to-noise and options for pre-designed panels or customized panels, Ultivue solutions are designed to label tissues for in-depth data mining for spatial phenomics. The ZEISS Axioscan automated whole slide imager offers unparalleled fluorescence imaging and resolution of multiplex immuno-labeled samples. Fast and gentle imaging ensures high productivity with little to no sample damage. With this collaboration, Ultivue and ZEISS will offer researchers a faster time to results from tissue labeling to image acquisition through analysis.
“At Ultivue, we have successfully scanned thousands of tissue sections stained with our multiplex assays with the ZEISS Axioscan to serve our biopharma customers. High throughput, quality, and cost-efficiency are key characteristics of a scalable workflow for tissue multiplexing. We are excited to deepen our relationship with ZEISS to further optimize the interplay of Ultivue assays and ZEISS instruments,” said Jacques Corriveau President and CEO of Ultivue.
“Building on our six-year relationship, we are looking forward to a deeper level of collaboration with Ultivue to co-market our complete end-to-end workflow for spatial phenotyping from staining to imaging to analysis,” said Joseph Huff, Head of Marketing North America ZEISS Research Microscopy Solutions.
Figure 1. Tonsil stained with Ultivue’s FixVUE Immuno8 panel and scanned using a ZEISS Axioscan.
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 7.5 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2021).
For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world’s leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.
With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company’s significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS’ technology and market leadership. ZEISS invests 13 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.
With around 37,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities (status: 31 March 2022). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.
Further information at www.zeiss.com
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at ultivue.com.Eva Categories: News Tags: Announcement